Dupilumab Discontinuation: Key Risk Factors for Recurrence
Summary of the Study on Dupilumab and Atopic dermatitis Recurrence
This retrospective study, conducted at Sichuan Provincial People’s Hospital in Chengdu, China between January 1, 2021, and December 31, 2023, investigated the rate of atopic dermatitis recurrence after discontinuing dupilumab treatment. Hear’s a breakdown of the key findings:
Study Details:
Participants: Patients treated with dupilumab for at least 4 weeks, following standard dosing, with complete medical records and follow-up. mean age was 37.3 years, and 42.6% were female.
Follow-up: Every 2 weeks after medication discontinuation until disease recurrence or the study end date.
Recurrence Rate: 23.4% (95% CI, 16%-30%)
Median Time to Relapse: 29 weeks (range, 22-59)
Mortality: One patient death during follow-up, unrelated to atopic dermatitis recurrence.
Key Risk Factors for Recurrence (Statistically Significant):
Comorbid Conjunctivitis: HR 7.912 (95% CI, 1.280-48.895; P =.026)
Dupilumab Treatment < 16 weeks: HR 5.871 (95% CI, 2.154-16.003; P = .001)
BMI ≥ 28 kg/m²: HR 5.653 (95% CI, 2.331-13.713; P < .001)
Male Sex: HR 5.634 (95% CI, 1.727-18.373; P = .004)
Familial Predisposition to Allergy: HR 3.438 (95% CI,1.351-8.747; P = .01)
Risk Factors Not Statistically Significant (but showed modest increases in risk):
Comorbid Urticaria
Comorbid Allergic Rhinitis
Factors Associated with Lower Risk of Recurrence:
Comorbid Asthma: HR 0.935
Previous Corticosteroid Treatment: HR 0.880
Age > 60: HR 0.763
Disease Duration ≥ 10 years: HR 0.761
Comorbid Chronic Bronchitis: HR 0.416
Study Strengths & Consistency with Previous Research:
The study findings align with previous research, notably regarding:
Male Sex: Increased risk of reduced drug survival and atopic dermatitis severity.
Allergic Rhinitis: Increased risk of reduced drug survival.
High BMI: Potential determinant of atopic dermatitis severity.
the study highlights the importance of identifying patients at higher risk of atopic dermatitis recurrence after dupilumab discontinuation and emphasizes the need for improved management strategies for relapsed disease. The investigators expressed concern about the lack of early intervention in relapse cases.